Depixus (formerly PicoSeq) is undertaking commercial development of a disruptive new technology for the fast, accurate, and inexpensive extraction of sequence and epigenetic information from long individual molecules of DNA and RNA.
Our MAGNA technology goes beyond decoding the static genetic code to reveal the dynamics of the genome that control health and disease.
Our MAGNA technology goes beyond decoding the static genetic code to reveal the dynamics of the genome that control health and disease.
Location: France, Ile-de-France
Employees: 11-50
Total raised: $35.4M
Founded date: 2012
Investors 2
| Date | Name | Website |
| - | Agoranov | agoranov.c... |
| - | Arix Biosc... | arixbiosci... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.12.2021 | Series A | $35.4M | - |
Mentions in press and media 1
| Date | Title | Description |
| 16.12.2021 | Depixus Raises USD35.4M in Series A Financing | Depixus, a Paris, France- and Cambridge, England, UK-based biotechnology company developing technology for the fast, accurate, and straightforward extraction of multiomic information from DNA, RNA, and proteins, raised USD35.4M in a Series ... |